Transient Ischemia without Thrombolytic: Inpatient Reimbursement Overview

DRG 069 addresses inpatient admissions for transient ischemia without thrombolytic therapy, focusing on short-stay medical management and observation for neurologic symptoms. It matters for inpatient reimbursement because proper diagnosis and coding determine payment under the prospective payment system and differentiate resource use from other cerebrovascular Diagnosis-Related Group categories.

Customize your policy alerts

Sign up for drg 069 policy alerts

Get alerted when payer policies referencing 069 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 069 Overview

DRG 069 covers inpatient encounters for transient ischemia without use of thrombolytic therapy, typically including transient ischemic attack presentations managed medically and observed for neurologic stability. This Diagnosis-Related Group groups cases with similar resource use and clinical severity for prospective payment under Medicare, influencing hospital reimbursement, length of stay expectations, and billing considerations. Accurate coding of diagnoses and comorbid conditions determines assignment to this Diagnosis-Related Group and affects payment relative to other cerebrovascular Diagnostic-Related Group categories.

Explore openpayer tools

View all tools

Transient Ischemia without Thrombolytic: Inpatient Reimbursement Overview

Customize your policy alerts

Sign up for drg 069 policy alerts

Get alerted when payer policies referencing 069 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 069 Overview

National Payment Rates

Across commercial payers the observed rate range for DRG 069 spans roughly $5K to $27K, with the widest spread between the minimum and maximum values seen in Anthem data. Refer to the payer table and the accompanying chart below for payer-specific percentiles and distributions. Cigna, Aetna, Anthem, and BCBS show notable variation around their medians.

The CMS 2023 data are national Medicare fee-for-service inpatient payment figures published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 069. These values summarize national Medicare payment experience for the period reported.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7.4K	$47K	$5.6K	28K

Patient Population

This DRG’s population skews toward Medicare-age beneficiaries rather than exclusively working-age commercial enrollees, reflecting a higher share of episodes in the Medicare population. Commercial payers represent a meaningful portion of cases as well, indicating a mixed-age cohort but with Medicare predominance. Expect the age distribution to include both older adults and some working-age patients covered by private/commercial insurers.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 069 mean reimbursements range from $12K to $19K across reported payers, with Cigna paying the most and BCBS and Anthem the least. Cigna’s mean ($19K) notably exceeds the national Cigna mean, while BCBS and Anthem sit at a lower, tightly clustered $12K. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $19K) is the highest payer among listed payers; lowest payers: BCBS and Anthem (both mean $12K).
Alaska’s payer means range ($12K–$19K) is compressed but Cigna’s mean sits above the national Cigna mean (~$13K), representing a meaningful upward deviation for that payer.
BCBS and Anthem means ($12K) align with or exceed some national medians, indicating limited downside risk compared with national variability.

Clinical Trials

Trials of early diagnostic and risk stratification strategies for transient ischemic attacks (TIAs) focus on rapid identification of patients at highest short-term stroke risk using combinations of clinical scores, neuroimaging protocols, and blood biomarkers. These studies enroll acute-care patients presenting to emergency departments or observation units within 24–72 hours of transient neurologic symptoms and evaluate which diagnostic algorithms most accurately predict subsequent stroke or need for inpatient admission. Findings are directly relevant to providers and payers because better early risk stratification can reduce unnecessary admissions, target scarce resources (advanced imaging, neurology consultation), and prevent costly readmissions or downstream stroke care.
Comparative effectiveness studies evaluate secondary prevention strategies initiated during the inpatient stay or observation period after a TIA, comparing different antithrombotic approaches, blood pressure and lipid management intensities, or combinations of interventions in diverse patient subgroups (eg, atrial fibrillation vs noncardioembolic TIAs). These trials typically follow patients for months to a year to measure recurrent stroke, major bleeding, functional outcomes, and healthcare utilization. Payers and hospitals benefit from evidence showing which inpatient-initiated prevention pathways most effectively reduce recurrence and long-term costs while balancing safety risks for the heterogeneous TIA population captured in this DRG.
Post-discharge care coordination and health-services research examines models of transitional care for TIA patients — for example, fast-track outpatient TIA clinics, telehealth follow-up, medication adherence interventions, and social determinant screening — assessing their impact on 30- and 90-day readmissions, outpatient utilization, and patient-reported outcomes. These studies enroll patients discharged from emergency departments or short inpatient stays and measure pragmatic outcomes important to systems: timeliness of specialist follow-up, adherence to guideline-recommended testing and therapies, and preventable utilization. Results inform providers and payers about scalable approaches to reduce avoidable readmissions and improve value-based care for the TIA population represented by this DRG.

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with MCC: Inpatient Reimbursement Overview

021-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITH-CC

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC: Inpatient Reimbursement Overview

022-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITHOUT-CC-MCC

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage without CC/MCC: Inpatient Reimbursement Overview

023-CRANIOTOMY-WITH-MAJOR-DEVICE-IMPLANT-OR-ACUTE-COMPLEX-CNS-PRINCIPAL-DIAGNOSIS-WITH-MCC-OR-ANTINEOPLASTIC-IMPLANT-OR-EPILEPSY-WITH-NEUROSTIMULATOR

Craniotomy with Major Device Implant or Complex CNS DRG 023: Inpatient Reimbursement Overview

024-CRANIOTOMY-WITH-MAJOR-DEVICE-IMPLANT-OR-ACUTE-COMPLEX-CNS-PRINCIPAL-DIAGNOSIS-WITHOUT-MCC

Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis without MCC: Inpatient Reimbursement Overview

025-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITH-MCC

Craniotomy and Endovascular Intracranial Procedures with MCC: Inpatient Reimbursement Overview

026-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITH-CC

Craniotomy and Endovascular Intracranial Procedures with CC: Inpatient Reimbursement Overview

027-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITHOUT-CC-MCC

Craniotomy and Endovascular Intracranial Procedures without CC/MCC: Inpatient Reimbursement Overview

028-SPINAL-PROCEDURES-WITH-MCC

Spinal Procedures with MCC: Inpatient Reimbursement Overview

029-SPINAL-PROCEDURES-WITH-CC-OR-SPINAL-NEUROSTIMULATORS

Spinal Procedures with CC or Spinal Neurostimulators: Inpatient Reimbursement Overview

Showing 1–10 of 71

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

National Payment Rates

Mean Rates by Payer — National — DRG 069

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7.4K	$47K	$5.6K	28K

Patient Population

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 069

Key Insights for Alaska

Highest payer: Cigna (mean $19K) is the highest payer among listed payers; lowest payers: BCBS and Anthem (both mean $12K).
Alaska’s payer means range ($12K–$19K) is compressed but Cigna’s mean sits above the national Cigna mean (~$13K), representing a meaningful upward deviation for that payer.
BCBS and Anthem means ($12K) align with or exceed some national medians, indicating limited downside risk compared with national variability.

Clinical Trials

Trials of early diagnostic and risk stratification strategies for transient ischemic attacks (TIAs) focus on rapid identification of patients at highest short-term stroke risk using combinations of clinical scores, neuroimaging protocols, and blood biomarkers. These studies enroll acute-care patients presenting to emergency departments or observation units within 24–72 hours of transient neurologic symptoms and evaluate which diagnostic algorithms most accurately predict subsequent stroke or need for inpatient admission. Findings are directly relevant to providers and payers because better early risk stratification can reduce unnecessary admissions, target scarce resources (advanced imaging, neurology consultation), and prevent costly readmissions or downstream stroke care.
Comparative effectiveness studies evaluate secondary prevention strategies initiated during the inpatient stay or observation period after a TIA, comparing different antithrombotic approaches, blood pressure and lipid management intensities, or combinations of interventions in diverse patient subgroups (eg, atrial fibrillation vs noncardioembolic TIAs). These trials typically follow patients for months to a year to measure recurrent stroke, major bleeding, functional outcomes, and healthcare utilization. Payers and hospitals benefit from evidence showing which inpatient-initiated prevention pathways most effectively reduce recurrence and long-term costs while balancing safety risks for the heterogeneous TIA population captured in this DRG.
Post-discharge care coordination and health-services research examines models of transitional care for TIA patients — for example, fast-track outpatient TIA clinics, telehealth follow-up, medication adherence interventions, and social determinant screening — assessing their impact on 30- and 90-day readmissions, outpatient utilization, and patient-reported outcomes. These studies enroll patients discharged from emergency departments or short inpatient stays and measure pragmatic outcomes important to systems: timeliness of specialist follow-up, adherence to guideline-recommended testing and therapies, and preventable utilization. Results inform providers and payers about scalable approaches to reduce avoidable readmissions and improve value-based care for the TIA population represented by this DRG.

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with MCC: Inpatient Reimbursement Overview

021-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITH-CC

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC: Inpatient Reimbursement Overview

022-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITHOUT-CC-MCC

Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage without CC/MCC: Inpatient Reimbursement Overview

023-CRANIOTOMY-WITH-MAJOR-DEVICE-IMPLANT-OR-ACUTE-COMPLEX-CNS-PRINCIPAL-DIAGNOSIS-WITH-MCC-OR-ANTINEOPLASTIC-IMPLANT-OR-EPILEPSY-WITH-NEUROSTIMULATOR

Craniotomy with Major Device Implant or Complex CNS DRG 023: Inpatient Reimbursement Overview

024-CRANIOTOMY-WITH-MAJOR-DEVICE-IMPLANT-OR-ACUTE-COMPLEX-CNS-PRINCIPAL-DIAGNOSIS-WITHOUT-MCC

Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis without MCC: Inpatient Reimbursement Overview

025-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITH-MCC

Craniotomy and Endovascular Intracranial Procedures with MCC: Inpatient Reimbursement Overview

026-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITH-CC

Craniotomy and Endovascular Intracranial Procedures with CC: Inpatient Reimbursement Overview

027-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITHOUT-CC-MCC

Craniotomy and Endovascular Intracranial Procedures without CC/MCC: Inpatient Reimbursement Overview

028-SPINAL-PROCEDURES-WITH-MCC

Spinal Procedures with MCC: Inpatient Reimbursement Overview

029-SPINAL-PROCEDURES-WITH-CC-OR-SPINAL-NEUROSTIMULATORS

Spinal Procedures with CC or Spinal Neurostimulators: Inpatient Reimbursement Overview

Showing 1–10 of 71

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

Transient Ischemia without Thrombolytic: Inpatient Reimbursement Overview

Sign up for drg 069 policy alerts

DRG 069 Overview

OpenPayer

Transient Ischemia without Thrombolytic: Inpatient Reimbursement Overview

Sign up for drg 069 policy alerts

DRG 069 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References